Logo image of NEUE

NEUEHEALTH INC (NEUE) Stock Fundamental Analysis

NYSE:NEUE - US10920V4041 - Common Stock

6.72 USD
0 (0%)
Last: 9/3/2025, 4:15:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NEUE. NEUE was compared to 102 industry peers in the Health Care Providers & Services industry. NEUE has a bad profitability rating. Also its financial health evaluation is rather negative. NEUE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year NEUE has reported negative net income.
In the past year NEUE has reported a negative cash flow from operations.
In the past 5 years NEUE always reported negative net income.
In multiple years NEUE reported negative operating cash flow during the last 5 years.
NEUE Yearly Net Income VS EBIT VS OCF VS FCFNEUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

With a Return On Assets value of -18.13%, NEUE is not doing good in the industry: 80.39% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -18.13%
ROE N/A
ROIC N/A
ROA(3y)-54.73%
ROA(5y)-42.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEUE Yearly ROA, ROE, ROICNEUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200 300

1.3 Margins

NEUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUE Yearly Profit, Operating, Gross MarginsNEUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

3

2. Health

2.1 Basic Checks

NEUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NEUE has more shares outstanding
The number of shares outstanding for NEUE has been increased compared to 5 years ago.
The debt/assets ratio for NEUE is higher compared to a year ago.
NEUE Yearly Shares OutstandingNEUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
NEUE Yearly Total Debt VS Total AssetsNEUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of -6.94, we must say that NEUE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NEUE (-6.94) is worse than 90.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.94
ROIC/WACCN/A
WACC6.02%
NEUE Yearly LT Debt VS Equity VS FCFNEUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B

2.3 Liquidity

NEUE has a Current Ratio of 2.70. This indicates that NEUE is financially healthy and has no problem in meeting its short term obligations.
NEUE's Current ratio of 2.70 is amongst the best of the industry. NEUE outperforms 83.33% of its industry peers.
A Quick Ratio of 2.70 indicates that NEUE has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.70, NEUE belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 2.7
NEUE Yearly Current Assets VS Current LiabilitesNEUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

5

3. Growth

3.1 Past

The earnings per share for NEUE have decreased strongly by -87.23% in the last year.
NEUE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.83%.
NEUE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.26% yearly.
EPS 1Y (TTM)-87.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.89%
Revenue 1Y (TTM)-13.83%
Revenue growth 3Y-14.76%
Revenue growth 5Y27.26%
Sales Q2Q%-7.48%

3.2 Future

Based on estimates for the next years, NEUE will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.62% on average per year.
NEUE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.81% yearly.
EPS Next Y14%
EPS Next 2Y11.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year28.84%
Revenue Next 2Y16.81%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NEUE Yearly Revenue VS EstimatesNEUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
NEUE Yearly EPS VS EstimatesNEUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -50 -100

0

4. Valuation

4.1 Price/Earnings Ratio

NEUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NEUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NEUE Price Earnings VS Forward Price EarningsNEUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEUE Per share dataNEUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.62%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for NEUE!.
Industry RankSector Rank
Dividend Yield N/A

NEUEHEALTH INC

NYSE:NEUE (9/3/2025, 4:15:01 PM)

6.72

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners51.74%
Inst Owner ChangeN/A
Ins Owners12.11%
Ins Owner Change49.96%
Market Cap60.61M
Analysts42.86
Price Target7.14 (6.25%)
Short Float %0.12%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)86.36%
Min EPS beat(2)61.7%
Max EPS beat(2)111.02%
EPS beat(4)3
Avg EPS beat(4)55.87%
Min EPS beat(4)-23.97%
Max EPS beat(4)111.02%
EPS beat(8)4
Avg EPS beat(8)68.26%
EPS beat(12)6
Avg EPS beat(12)40.72%
EPS beat(16)6
Avg EPS beat(16)0.91%
Revenue beat(2)0
Avg Revenue beat(2)-31.77%
Min Revenue beat(2)-33.05%
Max Revenue beat(2)-30.49%
Revenue beat(4)0
Avg Revenue beat(4)-18.95%
Min Revenue beat(4)-33.05%
Max Revenue beat(4)-2.77%
Revenue beat(8)1
Avg Revenue beat(8)-12.15%
Revenue beat(12)2
Avg Revenue beat(12)-15.49%
Revenue beat(16)2
Avg Revenue beat(16)-38.2%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)17.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.16
EYN/A
EPS(NY)-14.9
Fwd EYN/A
FCF(TTM)-8.23
FCFYN/A
OCF(TTM)-7.77
OCFYN/A
SpS98.72
BVpS-49.75
TBVpS-57.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.73%
ROA(5y)-42.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.2
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.87%
Cap/Sales 0.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.7
Quick Ratio 2.7
Altman-Z -6.94
F-Score4
WACC6.02%
ROIC/WACCN/A
Cap/Depr(3y)27.02%
Cap/Depr(5y)49%
Cap/Sales(3y)0.54%
Cap/Sales(5y)0.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.89%
EPS Next Y14%
EPS Next 2Y11.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.83%
Revenue growth 3Y-14.76%
Revenue growth 5Y27.26%
Sales Q2Q%-7.48%
Revenue Next Year28.84%
Revenue Next 2Y16.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y81.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year152.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.24%
OCF growth 3YN/A
OCF growth 5YN/A